Legend Biotech (LEGN) has attracted fresh attention after completing a follow on equity offering of American Depositary Shares worth about US$226 million, and releasing early clinical proof of concept data for its in vivo CAR T program LB2501.

Legend Biotech’s share price has been volatile around these updates, falling 16.7% on the day and 23.0% over the past week, yet still posting a 60.4% 90 day share price return while the 3 year total shareholder return is down 62.8%.

If you are looking beyond Legend Biotech to other potential opportunities in healthcare and AI driven therapies, this could be a good time to scan 41 healthcare AI stocks.

With Legend Biotech now trading well below its recent offer price yet still showing strong 90 day gains and an intrinsic value estimate above the market price, investors have to ask: is this pullback a buying opportunity, or is future growth already priced in?

Most Popular Narrative: 51.2% Undervalued

The most followed narrative on Legend Biotech pegs fair value around $57.24, a clear gap to the last close at $27.93, and builds a case on execution in multiple myeloma and cash flow potential under a 7.31% discount rate.

Significant expansion potential in both earlier lines of therapy and frontline settings for multiple myeloma, driven by strong survival data, ongoing clinical trials (CARTITUDE-5 and -6), and label updates that increase patient access, setting up long-term revenue acceleration as the patient pool widens.

Want to see what underpins that valuation gap on Legend Biotech? The narrative leans on aggressive revenue scaling, rising margins, and a future earnings multiple that assumes real staying power.

Result: Fair Value of $57.24 (UNDERVALUED)

However, the Legend Biotech narrative could be challenged if heavy reliance on CARVYKTI, intense competition, or ongoing high R&D and manufacturing costs weigh on long term profitability.

Next Steps

With mixed sentiment around Legend Biotech, this is a moment to move quickly, review the numbers yourself, and decide what really matters. To weigh both the concerns and the potential upside in context, start with the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Legend Biotech?

If Legend Biotech has sharpened your focus on where capital goes next, use this moment to scout fresh ideas instead of waiting on the sidelines.

• Spot potential mispricings by scanning companies that look cheap on quality and value metrics using the 45 high quality undervalued stocks.
• Prioritize resilience by reviewing businesses that pass strict financial health checks via the solid balance sheet and fundamentals stocks screener (48 results).
• Get ahead of the crowd by combing through a screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.